<DOC>
	<DOC>NCT00941057</DOC>
	<brief_summary>Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) and Dienogest (DNG) after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 2 mg Estradiol Valerate,3 mg Dienogest.Investigation of the bioequivalence of levomefolate calcium after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 0.451 mg levomefolate calcium</brief_summary>
	<brief_title>Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium</brief_title>
	<detailed_description />
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy postmenopausal women, age: 4575 years with body mass index between ≥18 and ≤30 kg/m2. Postmenopausal state revealed by: medical history, and hormone analyses in serum: estradiol ≤20 pg/mL and in women &lt;60 years old: folliclestimulating hormone ≥ 40 IU/L at screening Contraindications for use of combined (Estradiolvalerate/Dienogest) contraceptive (e.g.history of venous/arterial thromboembolic disease) Regular intake of medication Clinically relevant findings (ECG, blood pressure, physical and gynaecological examination, laboratory examination) Smoking</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>